Tenapanor

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 183 publications

Calcified amorphous tumor in a patient receiving peritoneal dialysis with severe, treatment-refractory hyperphosphatemia.

Calcified amorphous tumor in a patient receiving peritoneal dialysis with severe, treatment-refractory hyperphosphatemia.

Journal: Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis

Published: September 03, 2026

Correction to Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).

Correction to Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).

Journal: The American journal of gastroenterology

Published: July 14, 2026

Constipation with bloating: a clinical approach to evaluation and management.

Constipation with bloating: a clinical approach to evaluation and management.

Journal: Annals of medicine

Published: June 19, 2026

Pharmacological Management of Secondary Hyperparathyroidism in Dialysis Patients: A Narrative Review of Calcimimetics, Vitamin D Analogs, and Phosphate Binders.

Pharmacological Management of Secondary Hyperparathyroidism in Dialysis Patients: A Narrative Review of Calcimimetics, Vitamin D Analogs, and Phosphate Binders.

Journal: Cureus

Published: June 17, 2026

How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?

How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?

Journal: Expert opinion on pharmacotherapy

Published: June 10, 2026

Correction to: Long-Term Safety of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation in the T3MPO-3 Study.

Correction to: Long-Term Safety of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation in the T3MPO-3 Study.

Journal: Neurogastroenterology and motility

Published: June 08, 2026

Novel therapeutic approaches for phosphate regulation.

Novel therapeutic approaches for phosphate regulation.

Journal: Current opinion in nephrology and hypertension

Published: May 14, 2026

Correction to: Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).

Correction to: Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).

Journal: Kidney360

Published: May 07, 2026

Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.

Correction to: Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.

Journal: The American journal of gastroenterology

Published: May 04, 2026

Comparative Effectiveness and Safety of Phosphorus-Lowering Drugs for CKD 3-5 Stages.

Comparative Effectiveness and Safety of Phosphorus-Lowering Drugs for CKD 3-5 Stages.

Journal: Kidney medicine

Published: April 24, 2026

Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Correction to: Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.

Journal: Kidney360

Published: April 17, 2026

The Impact of Tenapanor on Serum Phosphate in Adult Dialysis Patients: A Narrative Review.

The Impact of Tenapanor on Serum Phosphate in Adult Dialysis Patients: A Narrative Review.

Journal: Kidney medicine

Published: April 17, 2026

Showing 1-12 of 183

Last Updated: 09/26/2026